MedTrace Logo

Low Molecular Weight hEparin vs. Aspirin Post-partum

NCT05058924 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-03-03

No results posted yet for this study

Summary

This is single centre pilot, randomized controlled trial assessing postpartum prophylactic anticoagulation with 3 weeks of LMWH followed by 3 weeks of Aspirin compared to standard of care of prophylactic LMWH for 6 weeks at moderate to high risk of developing VTE.

Conditions

  • Venous Thromboembolism

Interventions

DRUG

Prophylactic low molecular weight heparin

Enoxaparin 40 mg/dalteparin 5000 U/tinzaparin 4500 U subcutaneously daily for women with weight \<100 kg for 6 weeks.

DRUG

Low molecular weight heparin and low-dose aspirin

Enoxaparin 40 mg/dalteparin 5000 U/tinzaparin 4500 U subcutaneously daily for women with weight \<100 kg for three weeks followed by ASA 81 mg orally daily for three weeks.

Sponsors & Collaborators

  • Mount Sinai Hospital, Canada

    lead OTHER

Principal Investigators

  • Nadine Shehata, MD · Department of Medicine/IHPME, University of Toronto, Division of Hematology, Mount Sinai Hospital

  • Evanglia Vlachodimitropoulou Koumoutsea, MBBS · Department of Obstetrics and Gynecology, University of Toronto, Mount Sinai Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-29
Primary Completion
2024-02-29
Completion
2024-03-01

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05058924 on ClinicalTrials.gov